Research ArticleOpen AccessGoogle Scholar indexed
RETRACTED: Molecular Mechanism of KDM5B Development in Hepatocellular Carcinoma
Dean’s Office, The Fourth People’s Hospital of Haikou, Haikou, China
Dean’s Office, The Fourth People’s Hospital of Haikou, Haikou, China
- 1 Dean’s Office, The Fourth People’s Hospital of Haikou, Haikou, China
- 2 Dean’s Office, The Fourth People’s Hospital of Haikou, Haikou, China
Journal of Cancer Therapy·Volume 15 (2024)·Pages 1–12·Published 12 January 2024·DOI10.4236/jct.2024.151001
Copy link · social · email
Abstract
Short Retraction Notice The paper does not meet the standards of "Journal of Cancer Therapy ". This article has been retracted to straighten the academic record. In making this decision the Editorial Board follows COPE's Retraction Guidelines . The aim is to promote the circulation of scientific research by offering an ideal research publication platform with due consideration of internationally accepted standards on publication ethics. The Editorial Board would like to extend its sincere apologies for any inconvenience this retraction may have caused. Please see the article page for more details. The full retraction notice in PDF is preceding the original paper which is marked "RETRACTED".
KeywordsLiver CancerCyclin-Dependent Kinase (KDM5B)PathologyMolecular Mechanism
- Llovet, J.M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M. and Gores, G. (2016) Hepatocellular Carcinoma. Nature Reviews Disease Primers, 2, Article No. 16018. https://doi.org/10.1038/nrdp.2016.18
- Forner, A., Reig, M. and Bruix, J. (2018) Hepatocellular Carcinoma. Lancet, 391, 1301-1314. https://doi.org/10.1016/S0140-6736(18)30010-2
- Yang, J.D., Hainaut, P., Gores, G.J., Amadou, A., Plymoth, A. and Roberts, L.R. (2019) A Global View of Hepatocellular Carcinoma: Trends, Risk, Prevention and Management. Nature Reviews Gastroenterology & Hepatology, 16, 589-604. https://doi.org/10.1038/s41575-019-0186-y
- Zhu, A.X., Duda, D.G., Sahani, D.V., Jain, R.K. (2011) HCC and Angiogenesis: Possible Targets and Future Directions. Nature Reviews Clinical Oncology, 8, 292-301. https://doi.org/10.1038/nrclinonc.2011.30
- Villanueva, A. (2019) Hepatocellular Carcinoma. The New England Journal of Medicine, 380, 1450-1462. https://doi.org/10.1056/NEJMra1713263
- Yang, W.X., Pan, Y.Y. and You, C.G. (2019) CDK1, CCNB1, CDC20, BUB1, MAD2L1, MCM3, BUB1B, MCM2, and RFC4 May Be Potential Therapeutic Targets for Hepatocellular Carcinoma Using Integrated Bioinformatic Analysis. BioMed Research International, 2019, Article ID: 1245072. https://doi.org/10.1155/2019/1245072
- Giordano, S and Columbano, A. (2014) Met as a Therapeutic Target in HCC: Facts and Hopes. Journal of Hepatology, 60, 442-452. https://doi.org/10.1016/j.jhep.2013.09.009
- Llovet, J.M., Montal, R., Sia, D. and Finn, R.S. (2018) Molecular Therapies and Precision Medicine for Hepatocellular Carcinoma. Nature Reviews Clinical Oncology, 15, 599-616. https://doi.org/10.1038/s41571-018-0073-4
- Wang, D., Han, S., Peng, R., Jiao, C., Wang, X., Yang, X., Yang, R. and Li, X. (2016) Depletion of Histone Demethylase KDM5B Inhibits Cell Proliferation of Hepatocellular Carcinoma by Regulation of Cell Cycle Checkpoint Proteins p15 and p27. Journal of Experimental & Clinical Cancer Research, 35, Article No. 37. https://doi.org/10.1186/s13046-016-0311-5
- Bamodu, O.A., Huang, W.C., Lee, W.H., Wu, A., Wang, L.S., Hsiao, M., Yeh, C.T. and Chao, T.Y. (2016) Aberrant KDM5B Expression Promotes Aggressive Breast Cancer through MALAT1 Overexpression and Downregulation of hsa-miR-448, BMC Cancer, 16, Article No. 160. https://doi.org/10.1186/s12885-016-2108-5
- Gong, J., Yan, S., Yu, H., Zhang, W. and Zhang, D. (2018) Increased Expression of Lysine-Specific Demethylase 5B (KDM5B) Promotes Tumor Cell Growth in Hep3B Cells and is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma. Medical Science Monitor, 24, 7586-7594. https://doi.org/10.12659/MSM.910844